Oct 03, 2022 / 12:30PM GMT
Operator
And welcome to the Clene Inc. presentation of CNM-Au8 topline data from the Healey ALS Platform Trial conference call. Please note today's conference is being recorded. (Operator Instructions) At this time, I would like to turn the conference over to Rob Etherington, CEO of Clene. Mr. Etherington, you may begin your conference.
Rob Etherington - Clene Nanomedicine, Inc. - President & CEO
Thank you. Thank you very much. Welcome, everybody, to the Healey ALS Platform Trial results this morning. We are very grateful to have Dr. Merit Cudkowicz with us from the Healey ALS Platform Trial.
Dr. Merit Cudkowicz is the Chief of Neurology at Massachusetts General Hospital, the Director of the Sean M. Healey & AMG Centre for ALS. And she joins our Chief Medical Officer, Robert Glanzman, our Chief Development Officer, Michael Hotchkin, and myself to discuss these results.
I remind everybody of the forward-looking statement that is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that we
Clene Inc. To Discuss CNM-Au8 Topline Data From The HEALEY ALS Platform Trial Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot